CytomX Therapeutics 향후 성장

Future 기준 점검 0/6

CytomX Therapeutics 의 수익은 연간 11% 감소할 것으로 예상되는 반면, 연간 수익은 9.3% 로 증가할 것으로 예상됩니다. EPS는 연간 16.3% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 -53.9% 로 예상됩니다.

핵심 정보

-11.0%

이익 성장률

-16.33%

EPS 성장률

Biotechs 이익 성장	23.0%
매출 성장률	9.3%
향후 자기자본이익률	-53.94%
애널리스트 커버리지	Good
마지막 업데이트	02 Jan 2026

최근 향후 성장 업데이트

CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 16

Recent updates

CytomX Therapeutics: EpCAM Is Back, Now Prove It Holds (Rating Downgrade)

Dec 24

Analysts Just Shaved Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Forecasts Dramatically

Nov 13

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Soars 66% But It's A Story Of Risk Vs Reward

Oct 18

Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26%

Aug 14

Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching

Jun 18

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story

May 20

CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 16

Revenues Working Against CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Share Price Following 26% Dive

Apr 05

Advancements In CX-904 And CX-2051 May Drive Future Revenue Amid Funding Uncertainties

Feb 09 Multiple clinical readouts in 2025 could boost shareholder value and future revenue via new drug approvals.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Feb 04

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry

Dec 17

Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues

Oct 26

CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments

Jul 15

The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Jun 15

We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

May 09

CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling

May 02

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

Apr 27

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 25

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

Mar 05

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Jan 19

There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

Nov 26

We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Nov 17

이익 및 매출 성장 예측

NasdaqGS:CTMX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	49	-67	-48	-28	4
12/31/2027	35	-77	-36	-33	5
12/31/2026	31	-68	-50	-60	7
12/31/2025	83	-4	-33	-64	7
9/30/2025	114	28	-72	-72	N/A
6/30/2025	141	48	-78	-77	N/A
3/31/2025	148	42	-82	-81	N/A
12/31/2024	138	32	-87	-86	N/A
9/30/2024	127	14	-89	-88	N/A
6/30/2024	120	11	-86	-86	N/A
3/31/2024	119	17	-92	-91	N/A
12/31/2023	101	-1	-57	-56	N/A
9/30/2023	95	-10	-36	-35	N/A
6/30/2023	79	-42	-52	-51	N/A
3/31/2023	68	-71	-61	-60	N/A
12/31/2022	53	-99	-113	-111	N/A
9/30/2022	21	-149	-142	-141	N/A
6/30/2022	27	-143	-138	-136	N/A
3/31/2022	30	-132	-132	-130	N/A
12/31/2021	37	-116	-121	-119	N/A
9/30/2021	66	-72	-107	-105	N/A
6/30/2021	66	-64	-103	-100	N/A
3/31/2021	67	-61	23	25	N/A
12/31/2020	68	-65	3	5	N/A
9/30/2020	92	-54	-9	-7	N/A
6/30/2020	85	-63	-8	-5	N/A
3/31/2020	78	-76	-154	-151	N/A
12/31/2019	27	-133	-144	-140	N/A
9/30/2019	61	-99	-144	-140	N/A
6/30/2019	62	-99	N/A	-122	N/A
3/31/2019	75	-83	N/A	-100	N/A
12/31/2018	60	-85	N/A	-76	N/A
9/30/2018	75	-52	N/A	-25	N/A
6/30/2018	87	-39	N/A	-25	N/A
3/31/2018	74	-50	N/A	175	N/A
12/31/2017	72	-43	N/A	170	N/A
9/30/2017	51	-58	N/A	150	N/A
6/30/2017	30	-62	N/A	142	N/A
3/31/2017	24	-51	N/A	-16	N/A
12/31/2016	15	-59	N/A	-2	N/A
9/30/2016	11	-57	N/A	-12	N/A
6/30/2016	9	-57	N/A	-6	N/A
3/31/2016	8	-50	N/A	-28	N/A
12/31/2015	8	-42	N/A	-27	N/A
9/30/2015	8	-36	N/A	-24	N/A
6/30/2015	8	-26	N/A	30	N/A
3/31/2015	6	-24	N/A	31	N/A

애널리스트 향후 성장 전망

수입 대 저축률: CTMX 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -11%).

수익 vs 시장: CTMX 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -11%).

고성장 수익: CTMX 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: CTMX 의 수익(연간 9.3%)이 US 시장(연간 10.4%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: CTMX 의 수익(연간 9.3%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: CTMX는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/04 10:40
종가	2026/01/02 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

CytomX Therapeutics, Inc.는 19명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Peter Lawson	Barclays
Etzer Darout	Barclays
Ying Huang	BofA Global Research

CytomX Therapeutics 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 15% to US$7.07

Consensus revenue estimates decrease by 10%

CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Price target increased by 16% to US$5.50

Consensus EPS estimates increase by 32%

Consensus revenue estimates increase by 26%

Recent updates

CytomX Therapeutics: EpCAM Is Back, Now Prove It Holds (Rating Downgrade)

Investor sentiment improves as stock rises 16%

Analysts Just Shaved Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Forecasts Dramatically

Price target increased by 15% to US$7.07

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 10%

CytomX Therapeutics, Inc. to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer Annual Meeting

Investor sentiment improves as stock rises 17%

CytomX Therapeutics, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Cytomx Therapeutics Appoints Rachael Lester as Senior Vice President, Chief Business Officer

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Soars 66% But It's A Story Of Risk Vs Reward

Investor sentiment improves as stock rises 25%

Investor sentiment deteriorates as stock falls 16%

Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26%

CytomX Therapeutics, Inc. Provides Update on CX-2051 Phase 1 Study

Second quarter 2025 earnings released: US$0.001 loss per share (vs US$0.077 loss in 2Q 2024)

CytomX Therapeutics, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Chairman & CEO exercised options and sold US$149k worth of stock

Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching

Investor sentiment improves as stock rises 25%

Investor sentiment improves as stock rises 18%

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story

CytomX Therapeutics, Inc. Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (Pembrolizumab) in Patients with Metastatic Melanoma

CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Price target increased by 16% to US$5.50

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

CytomX Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $99.999999 million.

Investor sentiment improves as stock rises 44%

CytomX Therapeutics, Inc. to Report Q1, 2025 Results on May 12, 2025

CytomX Therapeutics, Inc., Annual General Meeting, Jun 11, 2025

Consensus EPS estimates increase by 32%

Revenues Working Against CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Share Price Following 26% Dive

Consensus revenue estimates increase by 26%

Full year 2024 earnings: EPS and revenues exceed analyst expectations

CytomX Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

CytomX Therapeutics, Inc. to Report Q4, 2024 Results on Mar 06, 2025

Price target increased by 13% to US$5.29

Advancements In CX-904 And CX-2051 May Drive Future Revenue Amid Funding Uncertainties

New minor risk - Share price stability

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Price target decreased by 12% to US$4.69

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry

Investor sentiment improves as stock rises 17%

Consensus estimates of losses per share improve by 61%

Consensus revenue estimates increase by 13%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

CytomX Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues

Investor sentiment improves as stock rises 17%

Consensus EPS estimates upgraded to US$0.29 loss

Consensus EPS estimates fall by 138%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 16%

New minor risk - Market cap size

CytomX Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments

CytomX Therapeutics, Inc. Promotes Chris Ogden to Chief Financial Officer

The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 35%

Investor sentiment deteriorates as stock falls 53%

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

Consensus EPS estimates fall by 29%

Price target increased by 47% to US$4.00

CytomX Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling